NDUFB2 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Auraptene (SCHEMBL2535029)	1.00	5/20
Auraptene (SCHEMBL2535034)	1.00	5/20
SCHEMBL8491443	0.56	4/20
SCHEMBL8489900	0.52	4/20
SCHEMBL8489907	0.52	4/20
SCHEMBL8492838	0.52	4/20
SCHEMBL8492845	0.52	4/20
SCHEMBL8489902	0.51	4/20
SCHEMBL8489908	0.51	4/20
SCHEMBL8491154	0.51	4/20
SCHEMBL8491160	0.51	4/20
SCHEMBL8491619	0.50	4/20
SCHEMBL8491624	0.50	4/20
SCHEMBL8491634	0.50	4/20
7-Prenyloxycoumarin (SCHEMBL4898255)	0.79	3/20
SCHEMBL712741	0.57	3/20
Geiparvarin (SCHEMBL2532495)	0.56	3/20
SCHEMBL6267768	0.55	3/20
SCHEMBL1095981	0.55	3/20
SCHEMBL4293165	0.55	3/20

Clinical trials — most relevant to NDUFB2 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Phase III Trial of Coenzyme Q10 in Mitochondrial Disease	PHASE3	COMPLETED
Coenzyme Q10 as a Symptomatic Treatment in Parkinson's Disease	PHASE3	COMPLETED
A Study of the Efficacy and Safety of MT1621 in Thymidine Kinase 2 (TK2) Deficiency (Treatment naïve)	PHASE3	WITHDRAWN
Mitochondrial Dysfunction in the Pathophysiology and Treatment of Bipolar Disorder	PHASE2	WITHDRAWN
A Study of Bezafibrate in Mitochondrial Myopathy	PHASE2	COMPLETED
A Study to Evaluate Vitamin B3 Derivative to Treat Mitochondrial Myopathy	PHASE2	ACTIVE_NOT_RECRUITING
Nicotinamide Riboside on Mitochondrial Function in Li-Fraumeni Syndrome	PHASE1/PHASE2	COMPLETED
Trial of Nicotinamide Riboside and Co-enzyme Q10 in Chronic Kidney Disease	PHASE2	COMPLETED
Parkinson's Disease Treatment With Coenzyme Q10	PHASE2	COMPLETED
Does Clinical Treatment of Mitochondrial Dysfunction Impact Autism Spectrum Disorder (ASD)?	PHASE1	UNKNOWN
Genomic Profiling of Mitochondrial Disease - Imaging Analysis for Precise Mitochondrial Medicine	nan	COMPLETED
Nicotinamide Riboside and Mitochondrial Biogenesis	nan	COMPLETED
The Natural History of Mitochondrial Diseases	nan	RECRUITING
North American Mitochondrial Disease Consortium Patient Registry and Biorepository (NAMDC)	nan	RECRUITING
Effect of Subtle Energy Transmission and Tao Calligraphy Mindfulness Practice on Mitochondrial DNA in Peripheral Blood Leukocytes	nan	NOT_YET_RECRUITING
Tissue Sample Study for Mitochondrial Disorders	nan	ENROLLING_BY_INVITATION
Abnormalities in the Effects of Insulin and Exercise on Glucose- and Lipid Metabolism in Obesity and Type 2 Diabetes	nan	COMPLETED
Identification of New Candidate Genes in Patients With Mitochondrial Disease by High Resolution Chromosome Analysis on DNA Chip	nan	COMPLETED
A Study Into the Underlying Biochemical Pathways Involved in Parkinson's Disease, Such as Mitochondrial (Cellular Powerhouse) Dysfunction	nan	COMPLETED
Identification of Large-Scale Mutations of POLG Gene by QMPSF in Patients With Mitochondrial DNA Instability.	nan	UNKNOWN
Natural History in Primary Mitochondrial Myopathies	nan	RECRUITING
MITOMICS : a Multi-OMICS Approach for the Diagnosis of Mitochondrial Diseases	nan	RECRUITING
Ccf mtDNA as a Neurodegenerative Biomarker	nan	UNKNOWN
Nicotinamide Riboside in Ulcerative Colitis	nan	RECRUITING
A RETROspective Study of Patients With TK2d	nan	COMPLETED
Assessing the Role of Mitochondrial Dysfunction in Primary Progressive Multiple Sclerosis	nan	UNKNOWN
GDF-15 as a Biomarker for Mitochondrial Disease	nan	COMPLETED
Exercise-mediated Rescue of Mitochondrial Dysfunctions Driving Insulin Resistance	nan	COMPLETED
Evaluation of Impact of Disease and Visual Disability on Quality of Life and Loss of Independence of Patients Living in France With Leber's Hereditary Optic Neuropathy (LHON) Through Qualitative and Quantitative Data Collection	nan	COMPLETED
Gastrointestinal Dysfunction in Children Affected With Mitochondrial Disorders	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a NDUFB2 binder may also engage these)

Protein	Name	Similarity
Q0MQC8	—	1.000	Q0MQC8 →
Q0MQC9	—	1.000	Q0MQC9 →
Q0MQC7	—	1.000	Q0MQC7 →
Q9CPU2	—	0.996	Q9CPU2 →
Q02374	—	0.992	Q02374 →
Q0MQJ3	—	0.986	Q0MQJ3 →
Q8HXG5	—	0.984	Q8HXG5 →
Q02380	—	0.983	Q02380 →
Q0MQJ4	—	0.982	Q0MQJ4 →
NDUFB11	NADH dehydrogenase [ubiquinone] 1 beta subcom	0.982	landscape →
P0CB69	—	0.980	P0CB69 →
P0CB70	—	0.980	P0CB70 →
Q5XG64	—	0.980	Q5XG64 →
Q9CQH3	—	0.980	Q9CQH3 →
NDUFB5	NADH-ubiquinone oxidoreductase SGDH subunit	0.979	landscape →
P24311	—	0.979	P24311 →
Q0MQD8	—	0.978	Q0MQD8 →
Q0MQJ5	—	0.978	Q0MQJ5 →
Q8TF08	—	0.977	Q8TF08 →
NDUFC1	NADH dehydrogenase [ubiquinone] 1 subunit C1,	0.977	landscape →
Q0MQF6	—	0.977	Q0MQF6 →
Q4QQV3	—	0.977	Q4QQV3 →
Q0MQF5	—	0.976	Q0MQF5 →
Q0MQD7	—	0.976	Q0MQD7 →
Q2M2S2	—	0.976	Q2M2S2 →
Q863G1	—	0.976	Q863G1 →
Q863G2	—	0.976	Q863G2 →
Q9D6U8	—	0.976	Q9D6U8 →
Q02376	—	0.976	Q02376 →
P80431	—	0.976	P80431 →